Suzanne Bruhn, PhD

Linkedin Team icon

Board Director, Chair of Compensation Committee, Member of Nomination & Governance Committee

Dr. Bruhn has served as an independent director of MindMed since August 2022. Dr. Bruhn is an accomplished life sciences executive and brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Bruhn is the president and CEO of Tiaki Therapeutics, a privately held biotech company with a platform focused on identifying drug targets for neuroinflammation in neurodegenerative diseases. Before that, she served as president and CEO of Proclara Biosciences, Inc., a clinical-stage company pioneering a novel approach to treat disorders of protein misfolding including Alzheimer’s and Parkinson’s Disease, as well as orphan amyloidosis. Prior to that she served as president and CEO of Promedior, Inc., a clinical-stage immunotherapy company developing targeted therapeutics to treat fibrosis. Prior to Promedior, she spent 13 years at Shire Human Genetic Therapies (HGT), a division of Shire PLC, specializing in the development and commercialization of treatments for orphan diseases, where she held a series of positions of increasing responsibility before serving as senior vice president of global regulatory affairs. During her tenure at Shire HGT, Dr. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management, and for global regulatory affairs. Prior to her time at Shire, Dr. Bruhn held various positions at Cytotherapeutics, Inc., a biotechnology company. Dr. Bruhn currently sits on the board of directors of Pliant Therapeutics, Inc. (NASDAQ: PLRX), Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vigil Neuroscience (NASDAQ: VIGL). Dr. Bruhn previously served on the boards of directors of Avalo Therapeutics, Inc. (fka Cerecor Inc.), a publicly traded pharmaceutical company (NASDAQ: AVTX); Aeglea BioTherapeutics, Inc., a publicly traded biotherapeutics company (NASDAQ: AGLE); Novelion Therapeutics, Inc., a biopharmaceutical company; and Raptor Pharmaceuticals Corp., a former publicly traded pharmaceutical company. Dr. Bruhn holds a Bachelor’s degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.

Paul Summergrad, MD

Professor of Psychiatry and Medicine at Tufts University School of Medicine and Chairman Emeritus of the department of psychiatry at Tufts Medical Center

Nzinga Harrison, MD

Co-Founder & Chief Medical Officer, Eleanor Health

Carol Vallone

Chair of the Board of Directors, Member of Compensation Committee, Member of Audit Committee

Andreas Krebs

Vice Chair of the Board of Directors, Member of Nomination & Governance Committee, Member of Audit Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Chair of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Chair of Compensation Committee, Member of Nomination & Governance Committee

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Stephanie Fagan, MS

Chief Corporate Affairs Officer

Carrie Liao, CPA

Chief Accounting Officer

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Gregg Pratt, PhD

Chief Regulatory and Quality Assurance Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office

Phong Duong, PharmD

VP, Global Market Access and Health Economics

Peter Mack, PhD

VP, Pharmaceutical Development

Rafael Muniz, MD

VP, Global Medical Affairs

Javier Muniz, MD

VP, Research and Development Strategy

Michael Seggev

VP, Global Marketing, Strategic Insights and Digital Innovation

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor
×

Thanks for visiting!

You are leaving MindMed and will be automatically redirected to ${url} in a moment.

Change your mind?

Return to Mindmed